Icure Pharmaceutical (XKRX:175250) COGS-to-Revenue : 0.84 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical COGS-to-Revenue?

Icure Pharmaceutical's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩18,700 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩22,131 Mil.

Icure Pharmaceutical's COGS to Revenue for the three months ended in Mar. 2025 was 0.84.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Icure Pharmaceutical's Gross Margin % for the three months ended in Mar. 2025 was 15.50%.

Icure Pharmaceutical COGS-to-Revenue Historical Data

The historical data trend for Icure Pharmaceutical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical COGS-to-Revenue Chart

Icure Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.80

1.07

1.09

0.98

0.89

Icure Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.86	0.88	0.85	0.95	0.84

Icure Pharmaceutical COGS-to-Revenue Calculation

Icure Pharmaceutical's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	61600.054	/	69207.254
	=	0.89

Icure Pharmaceutical's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	18700.155	/	22130.867
	=	0.84

Icure Pharmaceutical (XKRX:175250) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Icure Pharmaceutical's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	18700.155 / 22130.867
	=	15.50 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Icure Pharmaceutical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical Headlines

No Headlines